ERBB2 and neoplasm: To evaluate the molecular mechanisms involved in the implementation of the antitumor immune response and to identify the pathways of cytotoxicity realization of anti-HER2/neu TCR-engineered T cells at the moment of target cell engagement, we assessed their transcriptome in comparison to that of non-transduced T cells (LV-neg), following co-culture with HER2/neu-expressing SK-Mel-37 tumor cells (Figure 2).